Xapien GmbH

About
What does Xapien GmbH do?
Xapien GmbH offers an AI-driven platform that automates the process of collecting, analyzing, and summarizing public data for due diligence, risk assessment, and compliance. Their technology helps businesses quickly gain insights into individuals and entities, reducing manual effort and improving decision-making.
What is Xapien GmbH's valuation?
StartupHub estimates Xapien GmbH's effective valuation at $9.6M (range $6.3M to $15.0M, 10% confidence), based on comparable companies in the sector.
How much funding has Xapien GmbH raised?
Xapien GmbH has raised a total of $3M in funding. The most recent round on record is Seed.
Where is Xapien GmbH headquartered?
Xapien GmbH is headquartered in London, United Kingdom.
What industry does Xapien GmbH operate in?
Xapien GmbH operates in Due Diligence, Risk Management, Compliance Software, Regulatory Technology, RegTech, AI Search Engine.
How many employees does Xapien GmbH have?
Xapien GmbH has approximately 94 people on record.
Does Xapien GmbH have an affiliate program?
Yes, Xapien GmbH has an affiliate program. The program runs on Self-hosted affiliate. Register here: https://xapien.com/affiliates
AI-powered legal document review and analysis for law firms and legal departments.
AI-powered platform for understanding and managing complex legal documents.
AI-powered platform for secure and efficient due diligence and data room management.
AI-powered platform for fundraising and investor relations.
AI platform for professional services firms, automating legal research, contract analysis, and due diligence.
AI-powered platform for secure and efficient data room management for M&A and fundraising.
A platform for secure and efficient data room management for due diligence and transactions.
An entrant is a company tagged Due Diligence whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.
